Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Autoimmune Disorders and Interleukin-2 Therapy: A Step Toward 'Unanswered Questions'

Autoimmune Disorders and Interleukin-2 Therapy: A Step Toward 'Unanswered Questions' Abstract We read with interest the case of ''Recurrence of Pemphigus Vulgaris Associated With Interleukin-2 Therapy'' reported by Prussick et al1 in a recent issue of the ARCHIVES. Indeed, pemphigus vulgaris (PV) and various autoimmune disorders reported during interleukin-2 immunotherapy are diseases in which interleukin-2 might play a key role. Interestingly, these diseases are rare events during interleukin-2 immunotherapy, as discussed by Gaspari in his editorial.2 In our own series of 25 patients with metastatic melanoma,3 we observed mucocutaneous lesions in 15% of 78 cycles of interleukin-2 infusion. Nine biopsy specimens were studied and did not reveal histologic or direct immunofluorescence patterns of autoimmune bullous skin diseases. Nevertheless, we took a step toward Gaspari's ''unanswered questions'' concerning vitiligo and interleukin-2 therapy. Indeed, we had the opportunity to observe four cases of vitiligo in patients treated with interleukin-2 alone for metastatic melanoma out of our previous series of 25 References 1. Prussick R, Plott RT, Stanley JR. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy . Arch Dermatol. 1994;130:890-893.Crossref 2. Gaspari AA. Autoimmunity as a complication of interleukin 2 immunotherapy: many unanswered questions . Arch Dermatol. 1994;130:894-898.Crossref 3. Wolkenstein P, Chosidow O, Wechsler J, et al. Cutaneous side effects associated with interleukin-2 administration for metastatic melanoma . J Am Acad Dermatol. 1993;28:66-70.Crossref 4. Wolkenstein P, Chosidow O, Guillaume JC, Wechsler J, Avril MF, Revuz J. Lésions vitiligol̈des au cours des mélanomes métastasés traités par interleukine-2: four observations . Ann Dermatol Venereol. 1992;119:907-909. 5. Cohen Y, Haim S, Bartal A, Robinson E. Vitiligo associated with BCG-methanol extraction residue in malignant melanoma . Dermatologica. 1979;158:8-12.Crossref 6. Richards JM, Gilewksi TA, Ramming K, Mitchel B, Doane LL, Vogelzang NJ. Effective chemotherapy for melanoma after treatment with interleukin-2 . Cancer. 1992;69:427-429.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Autoimmune Disorders and Interleukin-2 Therapy: A Step Toward 'Unanswered Questions'

Loading next page...
 
/lp/american-medical-association/autoimmune-disorders-and-interleukin-2-therapy-a-step-toward-LWa4vhC0ga
Publisher
American Medical Association
Copyright
Copyright © 1995 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1995.01690170119022
Publisher site
See Article on Publisher Site

Abstract

Abstract We read with interest the case of ''Recurrence of Pemphigus Vulgaris Associated With Interleukin-2 Therapy'' reported by Prussick et al1 in a recent issue of the ARCHIVES. Indeed, pemphigus vulgaris (PV) and various autoimmune disorders reported during interleukin-2 immunotherapy are diseases in which interleukin-2 might play a key role. Interestingly, these diseases are rare events during interleukin-2 immunotherapy, as discussed by Gaspari in his editorial.2 In our own series of 25 patients with metastatic melanoma,3 we observed mucocutaneous lesions in 15% of 78 cycles of interleukin-2 infusion. Nine biopsy specimens were studied and did not reveal histologic or direct immunofluorescence patterns of autoimmune bullous skin diseases. Nevertheless, we took a step toward Gaspari's ''unanswered questions'' concerning vitiligo and interleukin-2 therapy. Indeed, we had the opportunity to observe four cases of vitiligo in patients treated with interleukin-2 alone for metastatic melanoma out of our previous series of 25 References 1. Prussick R, Plott RT, Stanley JR. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy . Arch Dermatol. 1994;130:890-893.Crossref 2. Gaspari AA. Autoimmunity as a complication of interleukin 2 immunotherapy: many unanswered questions . Arch Dermatol. 1994;130:894-898.Crossref 3. Wolkenstein P, Chosidow O, Wechsler J, et al. Cutaneous side effects associated with interleukin-2 administration for metastatic melanoma . J Am Acad Dermatol. 1993;28:66-70.Crossref 4. Wolkenstein P, Chosidow O, Guillaume JC, Wechsler J, Avril MF, Revuz J. Lésions vitiligol̈des au cours des mélanomes métastasés traités par interleukine-2: four observations . Ann Dermatol Venereol. 1992;119:907-909. 5. Cohen Y, Haim S, Bartal A, Robinson E. Vitiligo associated with BCG-methanol extraction residue in malignant melanoma . Dermatologica. 1979;158:8-12.Crossref 6. Richards JM, Gilewksi TA, Ramming K, Mitchel B, Doane LL, Vogelzang NJ. Effective chemotherapy for melanoma after treatment with interleukin-2 . Cancer. 1992;69:427-429.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: May 1, 1995

References